Comparative study of the effect of silver and selenium nanoparticles on bacterial and viral hepatic infection via modulating oxidative stress and DNA fragmentation

Sameh S. Gad

MSA university

sherine ibrahim (✉ sherinemahmoud@msa.eun.eg)

MSA university <https://orcid.org/0000-0002-2755-1641>

Sameh H. Ismail

Cairo university

Dina S. Abdelrahim

MSA university

Research article

Keywords: silver nanoparticles, selenium nanoparticles, oxidative stress, hepatitis B virus, interleukin-6, tumor necrosis factor - α

Posted Date: May 13th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-475473/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background: Nanoparticles are recently playing a potential role in improving drug uptake and the treatment of diseases. A variety of nanoparticles, such as selenium nanoparticles (SeNPs) and Silver nanoparticles (AgNPs) have been used as drug carriers in various ways for treatment of cancers and liver diseases. Our aim in this study is to investigate the ability of AgNPs and SeNPs to target and treat the viral and bacterial infection of liver in rats and cell lines.

Methods: For assessment of antioxidant activity of silver nanoparticles, six adult male albino rats were included in this study, liver slices were taken and assigned to 6 groups. Markers of hepatic functions, oxidative stress and inflammation in liver slices are carried out. While for assessment of antiviral activity of SeNPs, HBV-replicating human cell line HepG2 and normal human cell lines were used, hepatic and inflammatory alterations are determined through quantitative polymerase chain reaction (PCR) and comet assay techniques.

Results: The effect of Ag-NPs on interleukin-6 (IL-6) and tumor necrosis factor (TNF- α) levels were reduced in different treated groups with Ag-NPs compared with the control and diseased groups. On the other hand, SeNPs revealed significant alterations in the inflammatory markers as well as DNA damage in the treated HBV- human cell line HepG2 compared to the diseased ones.

Conclusion: Silver nanoparticles have the ability for producing various hepatic alterations and can inhibit the proliferation of hepatic stellate cells (HSCs) in a dose and size dependent manner. On the other hand, SeNPs showed excellent selectivity towards viral cells in the HepG2 cell lines. Both Ag-NPs and SeNPs might be a promising drug design for treating viral and bacterial liver diseases.

Introduction

Nanoparticles have been widely investigated over the past decades, due to their special physical and chemical properties. The main properties of nanomaterials depend mainly on their morphology and particle size. AgNPs and SeNPs are the most commercialized nanoparticles used in medical researches for medical applications such as gene, antimicrobial agents and drug delivery carriers (1).

AgNPs have been shown to significantly inhibit the replication of HBV (2). Additionally, these AgNPs have been used to target specific tissues and malignant cells in blood circulation through the combination of antibody-based targeting of ligands and material composition. These studies showed the potential effect of AgNPs for the cure of chronic liver disease including HBV infection and hepatic fibrosis (3).

Recently, traditional chemotherapy and anti-fibrotic treatments became ineffective in treatment of chronic liver diseases, due to the development of resistant drug tolerance. Thus, AgNPs may provide a safer therapeutic tool of treatment for targeting the hepatic stellate cells (HSCs), which are the main focus for treatment of liver cirrhosis and hepatic fibrosis (4).

SeNPs are regarded recently as new nanoparticles and have shown great interest due to their higher antioxidant, antiviral and anti-tumor activity, lower-toxicity to normal cells compared with other used nanoparticles (5). Taken into consideration, selenium (Se) is an essential element which has many important functions in the human body including protection of the cardiovascular and liver organs, regulation of secretion of hormones, and free radical scavenger. Recent studies have shown that SeNPs has potential therapeutic action for treatment of many diseases including inflammation, virus infection, and cancer (6). This new nanoparticle provides a promising tool for treatment of many liver diseases (7).

In this study, we will investigate the efficiency of different concentrations and particle sizes of AgNPs in treatment of liver bacterial infection in rats and the efficiency of SeNPs for targeting and treatment of HBV infected cell lines by evaluating their hepatic and inflammatory changes.

Materials And Methods

2.1 Preparation and synthesis of AgNPs

Two sizes of silver nanoparticles were purchased from (Egypt Center for nanotechnology), as small particle size (10 nm and 75 nm) and large particle size (250-300nm). The size, morphology and dispersion of the nanoparticles were characterized using a Tecnai™ G2 Twin Transmission Electron Microscope (FEI, Hillsboro, OR, USA) and dynamic light scattering (Compact Goniometer System 3; ALV-GmbH, Langen, Germany). Synthesis of silver nanoparticles was achieved by precipitation method using trisodium citrate (TSC) as reducing agent and capping one in the same time. AgNO₃ solution (0.03M) was dissolved in 200 mL deionized water, heated to boiling, then 0.3 M TSC was added drop by drop with slowly stirring and heated until the color of solution become pale yellow. The final solution was cooled at room temperature in isolated dark area to avoid lights (8).

2.1.2 Experimental animal design and conditions

Six adult male albino rats weighing from 200 to 250 gram were used. Rats were housed at MSA animal house under standard laboratory conditions and suitable temperature. They were housed in plastic cages, given standard normal diet and water. The work was done according to ethical committee guidelines in faculty of pharmacy and animal experimentations guideline at MSA University (**code: PH8/EC8/2019F**). After reaching to target weight (250 gm), animals were sacrificed to take their livers.

The livers were immediately freezed then kept in fridge for 24 hours. Then, according to Olinga and Sshuppan (2016), a precision cut liver slices was carried out using Cryostat macrotome device in Animal health research institute, the thickness of the slice was optimized to 150 micrometers. The freshly liver slices (14 slice each 150 µm thickness) are transferred to six well plate under controlled physiological conditions. We used six well plate and distribute the slices evenly, every well contained two slices exactly. So, all the wells contain the same weight and charactization. The six well plate were assigned to group 1: (Normal) containing Ringer solution only, group 2: (control) LPS 0.5 ml of (5 mg/ 13 ml distilled water) + Ringer solution, group 3: LPS +NAC + Ringer solution, group 4: (standard treatment) LPS 0.5 ml of (5 mg/

13 ml distilled water) + AgNpS(1-100 nm)+ Ringer solution, group 5: (treatment I) LPS 0.5 ml of (5 mg/ 13 ml distilled water) + AgNpL 0.5 ml (150-300 nm)+ 2 ml Ringer solution and group 6: LPS 0.5 ml of (5 mg/ 13 ml distilled water) + NAC + AgNpS(1-100 nm) 0.5 ml + 2 ml Ringer solution, Group 7: LPS 0.5 ml of (5 mg/ 13 ml distilled water) + NAC + AgNpL (150-300 nm) 0.5 ml + 2 ml Ringer solution. In all wells the ringer solution was added equally; The plates were then incubated in a humidified incubator in research lab at MSA University under conditions of 95% oxygen and 5% carbon dioxide to maintain slices viability. After 24-hour incubation, plates were gently removed and the supernatant and tissue homogenate were all collected and then subjected for analysis. Same steps were repeated six times with each rat n=6.

2.1.3 Hepatic function tests analysis:

Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were assayed in liver slices using (Biodiagnostics, CA, USA).

2.1.4 Oxidative stress analysis:

GSH assay: Liver slices were kept frozen at -20°C and tissue homogenate was made in glass homogenizer using 5% 5-suphosalicylic acid for (GSH). GSH level was assayed using the dithio-binitrobenzoic acid method (9).

2.1.5 Cytokine detection

The quantity of anti-inflammatory markers; IL-6 and TNF- α , in the liver slices homogenate -conditioned medium was quantified using an enzyme-linked immunosorbent assay (ELISA) kit (MyBiosource, Inc., San Diego., USA.) according to the manufacturer's instructions.

2.1.6 Histopathological Assessment

After fixation of liver specimens in 10% formaldehyde in PBS, liver slices were then dehydrated, embedded into paraffin and sections were made at a thickness of $5\mu\text{m}$. These sections were carefully stained with hematoxylin and eosin (H&E) for histopathology (10).

2.2 Preparation of selenium nanoparticles (Se-NPs)

Synthesis of Se-NPs have been done by precipitation – sono-chemical method using ascorbic acid and TSC as reducing- capping agent in the same time. Na_2SeO_3 solution (0.1M) was dissolved in 120 ml of doubled deionized water until the solution become colorless using ultrasound instrument Hielscher 400UP_S, Germany at amplitude of 74% for 1 minutes at temperature of 45°C . Then a mixture of ascorbic acid and TSC (0.2M to 0.1M for ascorbic acid and TSC, respectively.) are added drop by drop until the color of mixture become pale brown. The solution was cooled at room temperature in dark condition (11).

2.2.1 HBV infection and DNA analysis

HBV-replicating human HCC cell line HepG2. Were maintained in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum. Cell lines were cultured at 37°C in a humidified chamber supplemented with 5% CO₂. One group left as control and 2 groups were infected by HBV-positive sera.

Cells were incubated with HBV-positive sera (10⁹ particles/ml) for 14 h at 37°C, washed extensively with PBS and fresh medium was added. For PCR analysis, at 4 days post-infection cells were washed extensively in PBS, collected using a rubber policeman and lysed in a proteinase K lysis buffer for 6 h at 37°C, extracted with phenol–chloroform and precipitated with ethanol. The amount of DNA was determined by conducting semi-quantitative PCR analysis of HBsAg.

2.2.2 Determination of hepatic function tests and oxidative stress marker

The cell culture media from each of the 25 cm² culture flasks was collected, centrifuged at 3000×g for 10 min and stored at -70°C until assay. ALT and AST were assayed using (Biodiagnostics, CA, USA) while MDA was determined by thiobarbituric acid reactive substances (TBARS) method (12).

2.2.3 Cytokine detection

IL-2 was determined using IL-2 ELISA Kit (ab46032) and IL-8 was measured using IL-8 (CXCL8) ELISA Kit for cell culture supernatants by following the kit protocol while TNF-α was assayed by following the ELISA kit protocol (Cat: KIT10602) and TGF was measured using TGF -α Human (ab100647).

2.2.4 Quantification of HBV genomic DNA by Real time PCR

HBV genomic DNA extraction and sequencing analyses. HBV genomic DNA was extracted from the supernatants of co-cultured HepG2 cells using a Viral DNA Isolation Kit (Qiagen, germany) following the manufacturer's instructions. Briefly, cell supernatants were added to virus lysis buffer, and the lysates were loaded onto the spin column. After viral DNA was bound to the membrane, the column was washed and finally, the viral DNA was eluted. PCR was performed using HBV genomic DNA as template to amplify the X gene primer and probe sequences are as follows: forward primer HBV-F3, 5'-GGCCATCAGCGCATGC-3', and reverse primer HBV-R3M3, 5'-C [5-NitIdl] GCTGCGAGCAAAACA-3'; and probe HBV-P3, 5'-R-CTCTGCCGATCCATACTGCGGAACTC-Q-3. The PCR conditions were: initial denaturation at 94°C for 2 min, followed by 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min, and a final extension was performed at 72°C for 10 min.

2.2.5 Comet Assay

The extent of DNA damage was accessed using the comet assay under alkaline conditions. Comet tail length was measured by fluorescence microscopy and then analyzed using CaspLab Comet Assay Software v1.2.3 (Tritek Corporation, Summerduck, VA).

2.4 characterization of silver nanoparticles and selenium nanoparticles

2.4.1 Identification class:

X-ray Diffraction (XRD) Bruker D8 Discover device was used for XRD measurements. The X-ray source used was Cu K α radiation with a current of 32 mA and voltage of 41 kV. The 2 θ angles ranged from 20 to 70° for Se-NPs and from 35 to 90° for AgNPs with a scan speed of 0.3°/ min. The Raman spectra achieved by a Horiba lab RAM HR evolution spectrometer. The 532 nm edge laser line with Raman shift range from 100 to 1000 cm⁻¹ for Se-NPs and AgNPs range from 20 to 200 cm⁻¹, grating (450-850 nm) and ND filter 10% to prevent oxidation of Se-NPs and AgNPs. Acquisition time was 15 secs, accumulations of 4 without spike filter and objective was X100.

2.4.2 Index class:

BET method (the Brunauer– Emmett– Teller isotherm) used to determine the specific surface area by pore and surface area analyzer manufacturer by Quantachrome, model of NOVA touch LX2. Sample was degassed at 80°C for 3 h. under vacuum. DLS and zeta potential achieved by DLS and zeta potential analyzer (Malvern, UK).

2.4.3 Microscopic class:

Atomic Force Microscope (AFM) (5600LS, Agilent, USA) was used its 2D and 3D AFM images to determine surface topography of Se-NPs and AgNPs. Firstly, samples were prepared by subjecting samples to ultrasound waves for 15 minutes, a condition of 50 kHz, at an amplitude of 44% and 0.45 of a cycle (Up 400s manufacture by Hielscher, German). Finally, created a thin film using Spain coater instrument model Laurell-650Sz at the condition of 700 rpm under vacuum. AFM images and data profile have been done for 200 nm X 200 nm and its zoom 100 nm X 100 nm using contact mode, Al tap, 0.71 In/S speed, I. gain 2 and P. gain 4. Scanning electron microscopy (SEM) instrument have been done to study Se-NPs surface morphology. The SEM images was achieved by Jol 2000, Japan. Transmission electron microscopy (TEM) study was performed by added Se-NPs to deionized water and sonicating for 15 min using ultrasound prop with a 60 kHz, at an amplitude of 41% and 0.41 of a cycle (Up 400s, Hielscher, German). TEM experiments were achieved using (Jeol, JEM-2100 high-resolution, Japan).

2.5 Statistical Analysis

All data are expressed as mean $\pm$ SD. The difference between groups was statistically analyzed by GraphPad Prism 6 (La Jolla, CA, USA), using one-way ANOVA followed by Tukey's Kramer Multiple Comparison Test. P-value < 0.05 was considered as significant.

Results

3.1 Characterization of silver nanoparticles and selenium nanoparticles

Identification:

(XRD) pattern of Se-NPs showed the characteristic peaks for Se-NPs at $2\theta = 23.5^\circ, 29.6^\circ, 41.3^\circ, 43.5^\circ, 45.3^\circ, 48.2^\circ, 51.7^\circ, 56^\circ, 56.1^\circ, 61^\circ, 61.2^\circ, 65.2^\circ, 68.2^\circ$ and 68.4° which as shown in Fig. (1B). while XRD pattern of AgNPs illustrated the amorphous nature of Silver nanoparticles as shown in Fig. (2A). These results indicate the high crystallinity of Se-NPs. Concerning the Raman spectrum of colloidal Se-NPs, the characteristic Raman shift peaks was illustrated in Fig. (1A) without any shift or contaminated peaks with a very strong sharp peaks at 300cm^{-1} . While Raman spectra of amorphous AgNPs showed characteristic peaks at 52.1 and 146.5 of vibration AgNPs as illustrated in Fig. (2B).

Microscopic class:

2D and 3D AFM images and data showed that colloidal Se-NPs nanoparticles samples have excellent homogenous surface topography. In addition, AFM images illustrated the rode shape (blue) with excellent capping of citrate (green) composed core-shell nanostructure with dramatic shape and structure change where most of literature synthesis spherical Se-NPs and the cap was not recognized as shown in Fig. (3). While for AgNPs as shown in Fig. (4), AFM images showed its spherical shape with very sharp edges and homogenous in size and shape. Scanning Electron Microscope (SEM) and Transmission Electronic Microscope (TEM) results for AgNPs were found in accordance with AFM results as show in Fig. (6). Colloidal Se-NPs nanoparticles have rode core-shell nanostructure with very sharp edge of both core and shell with width size about 30 nm and length about 200 nm. While AgNPs have spherical shape with size range from 15 to 25 nm. Sem image also determined the rode core-shell nanostructure of Se-NPs and spherical shape of AgNPs as shown in figure (5).

Index class:

BET surface area measured for Se-NPs and AgNPs was $25.8\text{ m}^2/\text{g}$ and $70.1\text{ m}^2/\text{g}$ respectively. The Nitrogen adsorption-desorption isotherm curve shows unity IV type isotherms with mesopoues as shown in figure (7) for Se-NPs and IV type for AgNPs as shown in figure (8). Zeta sizing and potential illustrated in table (1) and figures (7 B and 8 B), the results showed the very strong stability of Se-NPs and AgNPs in aqueous solution due to its high zeta potential value which confirm the colloidal properties of both of them. The DLS curve for Se-NPs illustrated the presence of two sharp peaks at size about of 50 nm and 200 nm which confirm the presence of two sizes; one for length and other for width of rode core-shell nanostructure as shown in figure (7C). While AgNPs curve showed one sharp peak at 15 nm as shown in figure (8 C).

3.2 Interpretations of AgNPs

3.2.1 AgNPs Improved Liver Function Tests

In group treated with Ags (0 to 100 nm), ALT level was ranged from (31: 44 U/L) with the mean equal to $(37.5\text{ U/L} \pm 2.5)$ showing significant increase compared to normal ones but significant decrease in comparison to LPS groups ($P < 0.05$). Also, in group of Ag with large particle size, ALT level was ranged from (35: 46 U/L) indicating significant increase in comparison to normal group but significantly

decreased in comparison to LPS group ($P < 0.05$); while it shows no significant difference in comparison to group of Ag with small particle size. Similarly, AST level was ranged from (19: 22 U/L) with the mean equal to (20.3 U/L $\pm$ 0.6) showed significant decrease in comparison to LPS or NAC groups ($P < 0.05$). In NAC + AgL group, AST level showed (19.7 U/L $\pm$ 0.6) significant increase in comparison to normal while it causes a significant decrease in AST level in comparison to LPS or NAC group ($P < 0.05$) as shown in fig. (9 A&B)

3.2.2 Antioxidative and Anti-inflammatory Effects of AgNPs

The bacterial infection in LPS group resulted in a 2.6-fold decrease in the lipid peroxidation marker expressed as glutathione (GSH) compared with control liver slices indicating liver damage. Treatment with AgS increased GSH by around 40% and similarly In Ag L group, treatment caused 2-fold increase in GSH level compared to LPS group (Figure 9 C).

The anti-inflammatory properties of AgNPs in Liver slices were assessed by measuring the IL-6 and TNF- α levels. Treatment with both AgS and AgL resulted in the decrease of the anti-inflammatory IL-6 and the decrease of the pro-inflammatory TNF- α . Upon treatment with AgS, the IL-6 decreased by more than 1.6-folds while AgL decreased it by 1.5-folds. On the other hand, AgS treated group decreased TNF- α by 21% compared to the diseased LPS group while AgL surpassed this to reach 32% decrease in the levels of TNF- α as shown in fig. (10).

3.2.3 Histopathological Assessment

H&E staining revealed significant changes obtained in the histological examination between the control, LPS and treated groups with small and large particles of AgNPs. In the LPS group, the liver tissue shows activation of Kupffer cells and sporadic hepatocytes necrosis while both the AgS and the AgL groups showed slight activation of Kupffer cells and few necrosis effects of hepatocytes (Figure 11).

3.3 Interpretations of SeNPs

3.3.1 SeNPs Improved Liver Function Tests and reduced oxidative stress marker

After treatment of HBV-hepG2 cell lines with SeNPs, both ALT (U/L) and AST (U/L) levels were increased by 1.7 and 2.5-folds while the MDA concentration decreased. SeNPs administration enhanced the liver function tests and decreased the level of both enzymes as well as decreasing the secretion of MDA by 1.2-fold (Table 2).

3.3.2 Anti-inflammatory Effects of SeNPs in HBV-replicating human HCC cell line HepG2

SeNPs showed 1.3-fold and 1.5 decrease in both proinflammatory markers TNF- α and TGF levels in HepG2 cell lines after administering of SeNPs. These values were decreased significantly after treatment. Additionally, SeNPs decreased the level of IL-8 by 46 % and IL-2 by 43%. Treatment with SeNPs lowered the level of all proinflammatory markers significantly compared to the control group (Figure 12).

3.3.3 Effects of SeNPs on DNA fragmentation

The effect of the administration of SeNPs on DNA fragmentation in HepG2 cell lines is illustrated in Fig. 13. A significant more than 8-fold increase in the tail length and 3.7-fold increase in tail DNA% (tDNA%) was shown in the HepG2 cell lines infected with HBV. Treatment with SeNPs significantly protected HepG2 cell lines from DNA damage as indicated by a decrease the tail's length% by 24% and the tDNA% by 40% compared to the diseased group.

Discussion

Recently, studies focused on the ability of nanoparticles in drug delivery and targeting, leading to treatment of various liver diseases (13,14). Consequently, this study investigated the effects of both AgNPs and SeNPs on liver tissue injury due to viral and bacterial causes. The study showed different mechanisms for the effect of AgNPs on liver tissue even at low concentration; either through the particle size of the AgNPs or through the down regulation of secretion of cytokines by hepatic cells, which may lead to HSC activation.

Another evidence was observed in the histological changes including, necrosis and hepatocellular degeneration that were dose dependent. Several studies confirmed that liver is the main target organ for the effect of AgNPs and showed that liver tissue after treatment with AgNPs exposure may be associated with reduction of oxidative stress (15,16). It is known that oxidative stress is a main mechanism by which silver nanoparticle affect treatment of injured liver tissues (17,18). In this study, markers of oxidative stress and inflammatory mediators were measured in the liver tissues. We observed a significant decrease in GSH level and a significant increase in TNF- and IL-6 in hepatocytes. Our study suggests that the ability of AgNPs to cause a significant decline in the inflammatory markers leads to reduce apoptosis through inflammatory and oxidative stress mechanisms.

Several previous studies have focused on the effect of nanoparticle size on cytotoxicity and cellular uptake (19). In this study, AgNPs of two different sizes classified as small particle size (10 nm and 75 nm) and large particle size (250-300nm) at different concentrations were included in the treatment of bacterial infected liver slices together with NAC. Activation of HSCs is significant in development of liver disease through the secretion of many cytokines. The results of the Elisa assay demonstrated that the anti-inflammatory effects exerted by AgNPs on HSCs are size- and dose-dependent. Larger AgNPs showed significant reduction in TNF- α than the smaller particles, while for the anti-inflammatory marker, IL-6, both small and large particles showed significant reduction in IL-6 compared to the LPS group. According to our study, the other mechanism by which AgNPs can treat the liver bacterial infection occurs through its effects on the up-regulation of antioxidants (GSH) and this was clearly obvious in the groups treated with small and large AgNPs compared to LPS group.

Moreover, AgNPs affected successfully the liver function tests, this was confirmed by the significant decrease of AST and ALT levels in groups treated with NAC together with small and large particles compared with LPS group and group treated with NAC only, which indicate a significant protective role of

AgNPs. Therefore, the reducing effects of AgNPs on production of important cytokines as well as liver function tests which was also confirmed by other previous studies may suppress the progression of hepatic fibrosis; however, the detailed mechanisms require more studies (20). The size of AgNPs is highly significant in the cellular uptake by tissues, and thus affecting their bioactivity (21). the design of nanoparticles for medical applications should take into consideration the particle size to obtain the maximum effect.

There are several causes for chronic liver disease including; alcohol addiction, fatty liver, fibrosis, hepatitis B and C and cirrhosis (22). Recently SeNPs are considered a potential tool for treatment of cancers due to its chemical protective agent against toxic side effects of anticancer drugs (23). In the present study, the treatment of HBV-replicating human cell line HepG2 with SeNPs showed significant alterations in inflammatory mediators produced by injured liver tissue and DNA fragmentation.

Endocytosis has been proved as an important cellular uptake mechanism for nanoparticles. Many previous studies confirmed that selenium nanoparticles divide into smaller particles under the acidic conditions of the lysosomes, which helps the metabolism of SeNPs and the release of the loaded drugs (24).

Lipid peroxidation markers are products of oxidation and reduction process, including highly toxic compounds (25). These markers are considered to be a significant factor in cancer prevalence and recurrence. In addition, many studies have shown that alterations in lipid oxidation and inflammatory markers level in cells affect cell apoptosis and in turn could be used in treatment (26).

Our results agree with another study conducted by (27) who suggested that this injury is caused due to increase in the oxidative stress process in liver, and this was clearly obvious in our study which showed significant reduction in MDA levels in treated group with SeNPs compared to HepG2 cell lines. Moreover, our results were also confirmed by a recent study (24) which found that HBV causes inflammation and chronic liver injury which affects the damage of DNA, our current findings showed significant decrease in the inflammatory markers; TNF- α , TGF, IL-6 and IL-2 in the HepG2 cell lines treated with SeNPs compared to HBV-HepG2 cell lines. Additionally, the increase in DNA damage in HBV cell lines which may be due to the release of free radicals including nitric oxide reactive species (NOS) and reactive oxygen species (ROS) which leads to liver injury (28). These ROS led to inflammatory responses, necrosis of liver cells and fibrogenesis (29).

Our current results of comet assay showed that the treatment of HBV-cell lines with SeNPs caused significant decrease in DNA damage compared to HBV-cell lines, these results were reported also by another study (30). Taken into consideration, previous studies have shown that SeNPs has a significant therapeutic action for several diseases such as inflammation, cancer, and viral infection (31,32), for this reason, this nano system is drawing great attention in the field of therapy due to its higher stability, antiviral activity, anti-inflammatory activity and low toxicity compared to other nanoparticles.

Conclusion

In view of the present study, the efficacy of AgNPs was investigated by different biochemical approaches and it was particle dose and particle-dependent. The biochemical alterations in the inflammatory and oxidative stress markers may be an indication of the anti-inflammatory activity and the inhibitory activity of proliferation of injured cells caused by AgNPs in liver tissue. On the other hand, SeNPs played a potential role in reducing DNA damage as well as production of cytokines in HBV-cell lines. Taken together, both nanoparticles might be an innovative approach for treatment of viral and bacterial liver infection, however more studies are needed to support the use of AgNPs and SeNPs for human disease treatment and prevention.

Declarations

Authors' contributions: Sameh S. Gad and Sameh. H. Ismail participated in the study design, practical work especially the molecular biology as well as interpretation of data and manuscript preparation. Sherine M. Ibrahim and Dina S. Abdelrahim⁴ participated in practical work, interpretation of data and manuscript preparation

Acknowledgements: We would like to thank the animal house technicians for helping us in samples' collection.

Formatting of funding sources: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethical approval: The study protocol was approved by the Ethics Committee of the Faculty of Pharmacy, MSA University, Ethics Committee (code: PH8/EC8/2019F).

Conflict of interest: The authors declare that they have no conflict of interest.

Consent for publication

The signed Consent ensures that the Publisher has the Author's permission to publish the relevant Contribution.

Data Availability Statement: All data generated or analyzed during this study are included in this published article.

List Of Abbreviations

Aspartate transaminase: AST

Alanine transaminase: ALT

Enzyme-linked immunosorbent assay: ELISA

Glutathione: GSH

Hepatic stellate cells: HSC s

Hepatitis B virus: HBV

Interleukin -8: IL-8

Malondialdehyde: MDA

Hepatic stellate cells: HSC s

Hepatitis B virus: HBV

Interleukin -8: IL-8

Malondialdehyde: MDA

Nitric oxide reactive species: NOS

Silver nanoparticles: AgNPs

Selenium nanoparticles: SeNPs

Reactive oxygen species: ROS

Thiobarbituric acid reactive substances: TBARS

Trisodium citrate: TSC

Tumor necrosis factor: TNF- α

Tumor growth factor: TGF

Polymerase chain reaction: PCR

References

1. AshaRani PV, Low Kah Mun G, Hande MP and Valiyaveetil S: Cytotoxicity and genotoxicity of silver nanoparticles in human cells. *ACS Nano*. 3:279–290. 2009.
2. Xu X, Yang Q, Bai J, Lu T, Li Y and Jing X: Fabrication of biodegradable electrospun poly(L-lactide-co-glycolide) fibers with antimicrobial nanosilver particles. *J Nanosci Nanotechnol*. 8:5066–5070. 2008.
3. Lu L, Sun RW, Chen R, Hui CK, Ho CM, Luk JM, Lau GK and Che CM: Silver nanoparticles inhibit hepatitis B virus replication. *Antivir Ther*. 13:253–262. 2008.

4. Schroeder S, Heller DA, Winslow MM, et al: Treating metastatic cancer with nanotechnology. *Nat Rev Cancer*. 12:39–50. 2011.
5. Huang Y, Luo Y, Zheng J and Chen T, *ACS Appl. Mater. Interfaces*, 2014, 6, 19217 -19228
6. Tran P and Webster T, *Int. J. Nanomed.*, 2011, 6, 1553 -1558
7. Liu T, Zeng L, Jiang W, Fu Y, Zheng W and Chen T, *Nanomedicine*, 2015, 11, 947 –958
8. Choi, O. K., & Hu, Z. Q. (2008). Size dependent and reactive oxygen species related nanosilver toxicity to nitrifying bacteria. *Environmental Science and Technology*, 42, 4583–4588.
9. Rotruck JT, Pope AL, Ganther HE, et al (1973) Selenium: Biochemical role as a component of glutathione peroxidase. *Science* (80-) 179:588–590.
10. Suvana K S, Layton C BJ (2018) *Bancroft's theory and practice of histological techniques* (Eighth Edition).
11. Sameh Ismail, Gehad Mohamed, Aziza Amer, and Mohamed Amer, Comparative Killing Activity of Different Nanoparticles and Nanocomposites Based on *Dermanyssus gallinae*. *Nano Biomed. Eng.*, 2020, 12(4): 338-350.
12. Buege JA, Aust SD (1978) Microsomal Lipid Peroxidation. *Methods Enzymol* 52:302–310.
13. AshaRani PV, Low Kah Mun G, Hande MP and Valiyaveetil S: Cytotoxicity and genotoxicity of silver nanoparticles in human cells. *ACS Nano*. 3:279–290. 2009.
14. Lara HH, Ayala-Núñez NV, Ixtapan-Turrent L and Rodríguez-Padilla C: Mode of antiviral action of silver nanoparticles against HIV-1. *J Nanobiotechnology*. 8:1–10. 2010.
15. Wu Y, Zhou Q. Silver nanoparticles cause oxidative damage and histological changes in medaka (*Oryzias latipes*) after 14 days of exposure. *Environ. Toxicol. Chem.* . 2013;32:165–73. [PubMed] [Google Scholar]
16. Choi JE, Kim S, Ahn JH, Youn P, Kang JS, Park K, Yi J, Ryu DY. Induction of oxidative stress and apoptosis by silver nanoparticles in the liver of adult zebrafish. *Aquatic Toxicol.* . 2010;100:151–9.
17. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. *Nature* . 2006;311:622–7. [PubMed] [Google Scholar]
18. Liu Y, Guan W, Ren G, Yang Z. The possible mechanism of silver nanoparticle impact on hippocampal synaptic plasticity and spatial cognition in rats. *Toxicol. Lett.* . 2010;209:227–31. [PubMed]
19. Yuan Y, Liu C, Qian J, Wang J and Zhang Y: Size-mediated cytotoxicity and apoptosis of hydroxyapatite nanoparticles in human hepatoma HepG2 cells. *Biomaterials*. 31:730–740. 2010.
20. Abdelhalim MA and Jarrar BM: Gold nanoparticles induced cloudy swelling to hydropic degeneration, cytoplasmic hyaline vacuolation, polymorphism, binucleation, karyopyknosis, karyolysis, karyorrhexis and necrosis in the liver. *Lipids Health Dis*. 10:1662011.
21. Purohit V, Russo D. Cellular and molecular mechanisms of alcoholic hepatitis. *Alcohol*. 2002;27:3–6.
22. Li Y, Tian X, Lu Z, Yang C, Yang G, Zhou X, Yao H, Zhu Z, Xi Z and Yang X: Mechanism for alpha-MnO₂ nanowire-induced cytotoxicity in Hela cells. *J Nanosci Nanotechnol*. 10:397–404. 2010.

23. Karavelioglu E, Boyaci MG, Simsek N, et al. Selenium protects cerebral cells by cisplatin induced neurotoxicity. *Acta Cirúrgica Brasileira*. 2015;30(6):394-400
24. Gupta P, Bansal M., Koul A. Lycopene modulates initiation of N-nitrosodiethylamine induced hepatocarcinogenesis: studies on chromosomal abnormalities, membrane fluidity and antioxidant defense system. *Chem. Biol. Interact*. 2013;206:364–374.
25. Zhou , Y. Huang , F. Yang , W. Zheng and T. Chen , *Chem. –Asian J.*, 2016, **11**, 1008 –1009
26. Su , H. Lai , J. Chen , L. Li , Y.-S. Wong , T. Chen and X. Li , *PLoS One*, 2013, **8**, e63502
27. Buitrago-Molina L.E., Marhenke S., Longerich T. The degree of liver injury determines the role of p21 in liver regeneration and hepatocarcinogenesis. *Hepatology*. 2013;58:1143–1152.
28. Chen T., Wong Y.S. Selenocystine induces apoptosis of A375 human melanoma cells by activating ROS-mediated mitochondrial pathway and p53 phosphorylation. *Cell. Mol. Life Sci*. 2008; 65:2763–2775.
29. Novo E., Parola M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. *Fibrogen. Tissue Repair*. 2008; 1:5.
30. Abd El-Rahim A.H., Abd-Elmoneim O.M., Hafiz N.A. Assessment of Antigenotoxic Effect of Nanoselenium and Metformin on Diabetic Rats. *Jordan J. Biol. Sci*. 2017;10:159–165.
31. Feng J., Guo C., Zhu Y., Pang L, Yang Z., Zou Y. and Zheng X., *Int. J. Clin. Exp. Med.*, 2014, 7, 4063
32. Huang R., Chen C., Huang H., Chang C., Chen C., Chang C. and Hsieh M. , *Planta Med.*, 2000, 66 , 694 –698

Tables

Table (1) summery of Zeta size and Potential of all silver and selenium nanoparticles samples.

samples	Size (nm)	potential
Se-NPs	45	-32.1
Silver nanoparticles	15	-18.9

Table 2: Effect of SeNPs therapy on liver function enzymes and MDA in the studied groups.

Group	ALT (U/L)	AST (U/L)	MDA (g/dL)
Control	37.59 ± 3.56	38.42 ± 3.59	1.03 ± 0.18
HBV- HCC cell line HepG2 (HBV)	75.38 ^a ± 5.28	85.1 ^a ± 16.12	1.4 ^a ± 0.24
HBV- HCC cell line HepG2 treated with SeNPs (HBV-NP)	53.8 ^a ± 3.89	57.11 ^a ± 4.49	1.2 ^a ± 0.28

Statistical analysis was performed using one-way ANOVA followed by Tukey's multiple comparison post hoc test; ^a: significant difference versus the control group.

Figures

Figure 1

Illustrate Raman spectra (A) and XRD pattern (B) of Se-NPs.

Figure 2

Illustrate XRD pattern (A) and Raman spectra (B) of silver nanoparticles.

Figure 3

AFM image of colloidal Se-NPs nanoparticles A) 2D view AFM image of 200 nm X 200 nm size B) 3D view AFM image of 200 nm X 200 nm size C) 2D view AFM image of 100 nm X 100 nm size D) 3D view AFM image of 100 nm X 100 nm size.

Figure 4

AFM image of colloidal Silver nanoparticles A) 2D view AFM image of 200 nm X 200 nm size B) 3D view AFM image of 200 nm X 200 nm size C) 2D view AFM image of 100 nm X 100 nm size D) 3D view AFM image of 100 nm X 100 nm size.

Figure 5

Illustrate the A)TEM image and B)SEM image of Se-NPs

A)

B)

Figure 6

Illustrate the A) TEM and B) SEM image of Silver nanoparticles.

Figure 7

Illustrate A) isotherm of Se-NPs B) zeta potential of Se-NPs C) DLS of Se-NPs.

Figure 8

Illustrate A) isotherm of silver nanoparticles B) zeta potential of silver nanoparticles C) DLS of silver nanoparticles.

A)

B)

C)

Figure 9

(A) Effect of AgNps on ALT levels in the studied groups. (B) Effect of AgNps on AST levels in the studied groups (C) Effect of AgNps on MDA levels in the studied groups. Each value represents the mean of 6 experiments $\pm$ SD. a: significant difference versus the control group; b: significant difference versus the LPS group, c: significant difference versus the NAC group.

A)

B)

Figure 10

(A) Effect of therapy on the IL-6 levels in the studied groups. (B) Effect of therapy on the TNF- α levels in the studied groups. Each value represents the mean of 6 experiments $\pm$ SD. a: significant difference versus the control group; b: significant difference versus the LPS group; c: significant difference versus the NAC group; d: significance in relation to AgS.

Figure 11

H&E stain (x400) (A) Liver slices of control group showing no histopathological changes (B) Liver of LPS group showing Kupffer cells activation and necrosis of sporadic hepatocytes. (C) Liver slices treated with AgS showing some Kupffer cells activation and few necrosis of sporadic hepatocytes (D) Liver slices treated with AgL showing slightly Kupffer cells' activation and few necrosis of sporadic hepatocytes.

a: Significant difference in comparison to control Gp ($P<0.0001/n=6$)

A)

a: Significant difference in comparison to control Gp ($P<0.0001/n=6$)

B)

a: Significant difference in comparison to control Gp ($P<0.0001/n=6$)

C)

a: Significant difference in comparison to control Gp ($P<0.0001/n=6$)

D)

Figure 12

Effect of therapy on the TNF- α levels in the studied groups. (B) Effect of therapy on the TGF levels in the studied groups. (C) Effect of therapy on the IL-8 levels in the studied groups. (D) Effect of therapy on the IL-2 levels in the studied groups. Each value represents the mean of 6 experiments $\pm$ SD. a: significant difference versus the control group

Figure 13

Effect of treatment with SeNPs on DNA fragmentation. A: % Tail DNA. B: % Tail length. Both minimized DNA degradation but MSCs were 1.9-folds more protective. C: Comets from hepatocytes: a: control, b: HBV, c: SeNPs treated. Each value represents the mean of 10 experiments $\pm$ SD. a: significant difference versus the control group; b: significant difference versus the HBV group.